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Refractive error is the leading cause of visual impair-
ment, and the second leading cause of blindness worldwide 
[1]. Precise developmental regulation of ocular axial length 
is essential to avoid refractive error, and the study of rare 
inherited refractive disorders has highlighted several critical 
genes and molecular pathways.
One of these rare disorders is nanophthalmos, character-
ized by high hyperopia associated with a reduction in posterior 
and anterior segment length, and a predisposition to primary 
angle-closure glaucoma [2,3]. Variants in at least four genes 
have been associated with nanophthalmos, with the majority 
due to recessive variants in membrane frizzled-related protein 
(MFRP; OMIM: 606227) [4] or protease, serine, 56 (PRSS56; 
OMIM: 613858) [5-7]. In rare cases, nanophthalmos may be 
inherited as a dominant trait, and we and others have reported 
two families segregating heterozygous missense variants in 
transmembrane protein 98 (TMEM98; OMIM: 615949) [8,9]. 
Common variants in PRSS56 and TMEM98 have also been 
implicated in multiple independent genome-wide associa-
tion studies of myopia [10-12], highlighting the importance 
of studying nanophthalmos and other extremes of refractive 
error to understand the broader biology of common errors of 
refraction.
The latest gene to be implicated in nanophthalmos is 
myelin regulatory factor (MYRF; OMIM: 608329). The 
dominant NNO1 locus (OMIM: 600165), initially mapped to 
chromosome 11 in a large family in 1998 [13], was recently 
found to harbor a C-terminal essential splice variant in MYRF 
[14], with simultaneous independent reports of other variants 
in nanophthalmos and high hyperopia [15,16]. We describe an 
additional family with dominant high hyperopia and nanoph-
thalmos, and reveal a segregating heterozygous frameshift 
variant in MYRF.
METHODS
Human subjects: Patients and family members were recruited 
under the Australian and New Zealand Registry of Advanced 
Glaucoma [17]. Written informed consent was provided under 
protocols approved by the Southern Adelaide Clinical Human 
Research Ethics Committee (305–08), and adhering to the 
tenets of the Declaration of Helsinki.
DNA sequencing and analysis: DNA was prepared from whole 
blood and subjected to exome capture (Agilent SureSelect 
v5, Santa Clara, CA) as described [18]. DNA was prepared 
from venous blood samples, after temporary storage at -80°C, 
using the QIAGEN DNeasy Blood and Tissue Kit (Hilden, 
Germany), according to the manufacturer’s instructions. 
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Purpose: Nanophthalmos is a rare subtype of microphthalmia associated with high hyperopia and an increased risk 
of angle-closure glaucoma. We investigated the genetic cause of nanophthalmos and high hyperopia in an autosomal 
dominant kindred.
Methods: A proband with short axial length, high hyperopia, and dextrocardia was subjected to exome sequencing. 
Human and rodent gene expression data sets were used to investigate the expression of relevant genes.
Results: We identified a segregating heterozygous frameshift variant at the 3′ end of the penultimate exon of MYRF. 
Using Myc-MYRF chromatin immunoprecipitation data from rat oligodendrocytes, MYRF was found to bind immedi-
ately upstream of the transcriptional start site of Tmem98, a gene that itself has been implicated in autosomal dominant 
nanophthalmos. MYRF and TMEM98 were found to be expressed in the human retina, with a similar pattern of expression 
across several dissected human eye tissues.
Conclusions: C-terminal variants in MYRF, which are expected to escape nonsense-mediated decay, represent a rare 
cause of autosomal dominant nanophthalmos with or without dextrocardia or congenital diaphragmatic hernia.
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Paired-end libraries were generated and sequenced on an 
Illumina NovaSeq 6000 (San Diego, CA) instrument, with 
reads aligned to the GRCh37 human reference, and variants 
were joint called across samples according to GATK Best 
Practice workflows. Variant annotation was performed using 
Variant Effector Predictor (VEP) [19], and annotated Variant 
Call Format (VCF) files packaged into Gemini databases for 
downstream analysis [20]. MYRF variant and exon coordi-
nates refer to consensus transcript (NM_001127392.3) and 
protein (NP_001120864.1) sequences. Protein domains were 
as defined by UniProt (Q9Y2G1). Genomic Evolutionary 
Rate Profiling (GERP) constrained elements were defined 
by alignments across 35 mammalian species, and overlaid in 
Ensembl. MYRF variants were confirmed in a National Asso-
ciation of Testing Authorities (NATA)-accredited laboratory 
(SA Pathology, Flinders Medical Centre, Adelaide, Australia) 
using bidirectional capillary sequencing of the relevant PCR-
amplified MYRF region. PCR products were sequenced 
and base called on an Applied Biosystems 3130xl Genetic 
Analyzer (ThermoFisher Scientific). PCR was performed 
using 100 ng of genomic DNA template in an AmpliTaq Gold 
reaction mix (Thermo Fisher Scientific, Waltham, MA). The 
following standard PCR conditions were used on a Veriti 
(Thermo Fisher Scientific) thermal cycler: Step 1, 95 °C for 
10 min; Step 2, 95 °C for 30 s, 55 °C for 30 s, 72 °C for 1 
min, repeated for 40 cycles; and Step 3, 72 °C for 7 min. 
PCR amplified products were prepared for sequencing with 
the ExoSAP method using 10 μl of each PCR reaction treated 
with 5 U of Exonuclease I (New England Biolabs, Ipswich, 
MA) and 1 U of Shrimp Alkaline Phosphatase (USB Corpora-
tion, Cleveland, OH) to remove residual primers and dNTPs. 
Bidirectional BigDye Terminator Cycle Sequencing (Thermo 
Fisher Scientific) reactions of the appropriate template and 
PCR primer were resolved and base called on an Applied 
Biosystems 3130xl Genetic Analyzer (Thermo Fisher Scien-
tific). Detection of sequence variants was performed with 
the aid of Mutation Surveyor v4.0 (SoftGenetics LLC, State 
College, PA), with trace files assembled against the MYRF 
(NM_001127392.3) hg19 reference. The variant was depos-
ited in ClinVar, with accession number VCV000635185.1.
Gene expression analysis: Expression of human MYRF 
(204073_s_at) and TMEM98 (gnf1h00184_at) in selected 
tissues was retrieved from the GeneAtlas U133A data set [21]. 
Human cadaveric eye tissue dissection and RNA sequencing 
(RNA-seq) were performed as described [22]. Cadaveric 
human eyes with no known ocular disease were obtained 
from the Eye Bank of South Australia (Adelaide, Australia). 
Tissue dissection was performed under light microscope with 
a mean post-mortem time of 9.7 ± 5.3 h. Tissue from corneal 
epithelium, corneal stroma, corneal endothelium, trabecular 
meshwork (TM), pars plicata of the ciliary body, retina, 
optic nerve head, and optic nerve were collected and fixed 
in RNAlater solution (Thermo Fisher Scientific) for approxi-
mately 5 days prior to storage at -80 °C. A standard Trizol 
extraction protocol was used for RNA isolation (Thermo 
Fisher Scientific). RNA extracted from the pars plicata was 
passed through a Genomic-tip 20/G (QIAGEN, Hilden, 
Germany) as per the manufacturer’s instructions to remove 
excess melanin. RNA quality was assessed using the Agilent 
Bioanalyzer 2100 RNA 6000 Nano Assay (Santa Clara, CA; 
mean RIN = 6.5 ± 1.8). A Qubit 2.0 Fluorometer (Thermo 
Fisher Scientific) was used to quantify RNA.
RESULTS
We ascertained a 35-year-old female proband of European 
ancestry with high hyperopia (+13.00 D), and short axial 
lengths (17.53 to 17.72 mm), who had previously undergone 
bilateral peripheral iridotomies for angle closure (Figure 1A). 
This trait appeared to segregate in a fully penetrant autosomal 
dominant manner across four generations (Figure 1A). The 
daughter of the proband (IV:1) had shallow anterior chambers 
(1.98 to 2 mm) with no visible angle structures and associ-
ated ocular hypertension (28 to 30 mmHg), for which she was 
treated with bilateral peripheral iridotomies. The proband’s 
son (IV:2), had deep anterior chambers (3.67 to 3.7 mm) 
and no ocular hypertension. Examination of the proband’s 
father (II:1) was remarkable for disc crowding. None of the 
affected family members had glaucoma at their most recent 
follow-up. Microcornea, papillomacular folds, uveal effu-
sion syndrome, or marked vascular tortuosity was absent. 
The medical history of the index case (III:2) and her brother 
(III:3) was remarkable for dextrocardia, and although there 
were no reported genitourinary abnormalities, a routine chest 
X-ray in her affected son (IV:2) revealed an incidental right 
congenital diaphragmatic hernia (Figure 1B). The spectrum 
of the clinical details for all examined family members is 
summarized in Table 1.
Exome sequencing was performed on DNA from 
the proband, with no evidence of rare variants (gnomAD 
maximum allele frequency <0.01) predicted to be deleterious 
(Phred-scaled CADD score >10) in canonical transcripts 
of the previously known nanophthalmos genes (TMEM98, 
PRSS56, or MFRP). Given the phenotypic similarities of this 
case with a recently described family segregating an essential 
splice variant in MYRF [14], we searched for rare variants in 
the same gene. This revealed a heterozygous 1 bp deletion in 
MYRF (NM_001127392.3 c.3361delC), absent from gnomAD 
(v2.1.1), and predicted to introduce a C-terminal frameshift 
at codon 1121, followed by a premature termination codon 
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Figure 1. Autosomal dominant nanophthalmos and high hyperopia associated with a heterozygous frameshift variant in MYRF. A: Nanoph-
thalmos pedigree showing affected (filled) and unaffected (unfilled) members. Asterisks indicate individuals in which the c.3361delC 
variant was confirmed with capillary sequencing. B: Chest X-ray of the proband’s son (IV:2) showing a right congenital diaphragmatic 
hernia. C: Capillary sequencing trace of the MYRF c.3361delC variant in the proband (III:2), showing the reference and frameshifted 
variant sequences above and below the trace, respectively. D: Expanded cDNA and translated protein sequences from the MYRF reference 
sequence (NM_001127392.3), and the c.3361delC variant. Sequence encoded by the penultimate exon (exon 26) is highlighted in blue, 
with the frameshifted protein sequence highlighted in red. The c.3361 nucleotide is marked with an asterisk. E: MYRF locus schematic, 
showing the location of the variant described here (black symbol) and its proximity to variants described previously (gray [14] or white [15] 
symbols). F: MYRF protein schematic, showing the location of individual domains, and relative positions of reported disease-associated 
variants associated with nanophthalmos or high hyperopia (squares), or syndromic presentations (colored circles). Symbols (^) indicate 
nanophthalmos or high hyperopia variants associated with syndromic features. CC, coiled-coil domain; TM, transmembrane domain; red 
asterisk indicates the autolytic cleavage site.
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36 amino acids later in the terminal exon (NP_001120864.1 
p.(Arg1121Glyfs*36); Figure 1C,D). This variant was vali-
dated with capillary sequencing in the proband (III:2), and all 
available affected family members (II:1, III:3, IV:1, and IV:2).
Compared to previously reported MYRF variants asso-
ciated with congenital diaphragmatic hernia, congenital 
heart disease, and/or genitourinary abnormalities [23-27] 
(Figure 1E,F), the variant described here was at the 3′ end 
of the penultimate exon of MYRF, and therefore, may escape 
nonsense-mediated decay due to the introduction of a prema-
ture termination codon in the terminal exon (Figure 1D) [28]. 
The only described variants further downstream have been 
associated with isolated nanophthalmos and incompletely 
penetrant dextrocardia [14], or high hyperopia [15].
MYRF is translated as an endoplasmic reticulum (ER) 
membrane-bound protein, and following homotrimerization, 
is autoproteolytically cleaved to release an N-terminal tran-
scriptional activator that translocates to the nucleus. One such 
transcriptional target is thought to be TMEM98, for which 
heterozygous variants have also been described to cause 
nanophthalmos [8,9]. Using a chromatin immunoprecipitation 
data set from rat oligodendrocytes probed with a Myc-MYRF 
construct [14], we identified a binding peak immediately 
upstream of and overlapping the Tmem98 transcriptional start 
site, which also overlaps a genetic element constrained across 
35 mammalian species (Figure 2A). MYRF and TMEM98 
were highly expressed in the human retina, with MYRF also 
highly expressed in the brain (Figure 2B). Within tissues of 
dissected cadaveric human eyes, MYRF and TMEM98 shared 
an expression pattern more similar to one another than to 
MFRP and PRSS56 (Figure 2C).
DISCUSSION
MYRF was initially described as a transcriptional regulator 
essential for oligodendrocyte differentiation and myelin gene 
expression [29]. Missense, nonsense, frameshift, and essen-
tial splice variants in MYRF have since been implicated in 
syndromic presentations of congenital diaphragmatic hernia, 
congenital heart disease, and genitourinary abnormalities 
[23-27]. For those with available mortality data, 2/6 died 
within the first month of life, with a third case electively 
terminated at 19 weeks’ gestation [27]. At least one syndromic 
case also was associated with extreme hyperopia and short 
axial length [14], although it is unclear if detailed ocular 
examinations have been performed on other syndromic cases. 
Figure 2. Coordinated expression of MYRF and TMEM98 in human and rodent tissues. A: Myc-MYRF chromatin immunoprecipitation 
binding peak (highlighted in red) at the Tmem98 locus in rat oligodendrocytes. Intervals constrained across 35 mammalian species are 
highlighted in green. B: Mean expression of MYRF and TMEM98 in human tissue as measured with gene expression array [21]. C: Expression 
of MYRF and TMEM98 transcripts in dissected human cadaveric eye tissue, represented as reads per kilobase per million mapped reads 
(RPKM). Bars represent mean with standard error of the mean (SEM; n=5–7 biologic replicates per tissue). S, sclera; CS, corneal stroma; 
CE, corneal epithelium; TM, trabecular meshwork; DM, Descemet’s membrane; ON, optic nerve; ONH, optic nerve head; PI, peripheral 
iris; CB, ciliary body.
Molecular Vision 2019; 25:527-534 <http://www.molvis.org/molvis/v25/527> © 2019 Molecular Vision 
532
Similarly, it is unclear to what extent cardiac, diaphragmatic, 
and urogenital abnormalities have been investigated in indi-
viduals with apparently isolated nanophthalmos or hyperopia: 
Congenital diaphragmatic herniation was an incidental 
finding in at least one member of the kindred presented here.
The family presented here, along with others reported 
recently [14-16], represents a milder clinical presentation 
of MYRF-associated disease, with nanophthalmos or high 
hyperopia associated only occasionally with dextrocardia 
or congenital diaphragmatic hernia. There appear to be at 
least two important genetic distinctions between syndromic 
and non-syndromic MYRF variants. First, all syndromic 
MYRF variants reported thus far were found to be de novo, 
while at least three kindreds with nanophthalmos or high 
hyperopia show germline transmission of MYRF variants 
across multiple generations. Second, half (5/10) of the variants 
associated with nanophthalmos or high hyperopia occur in 
the final four exons of MYRF, or their associated splice sites. 
Three of these five affect either the terminal exon or the 3′ 
end of the penultimate exon, with a predicted termination 
codon introduced after read-through into the final intron. 
These three variants would, therefore, be expected to evade 
nonsense-mediated decay due to the 50 bp rule [28], and 
thus, be translated into protein with an altered C-terminus 
projecting into the ER lumen. The most C-terminal variant 
reported in a syndromic case to date is p.(Glu1081Glyfs*5), 
which lies in exon 25, and thus, expected to be degraded by 
nonsense-mediated decay [27]. Therefore, it would appear 
that more severe syndromic presentations are usually associ-
ated with MYRF haploinsufficiency, while isolated nanoph-
thalmos may sometimes be a consequence of hypomorphic, 
dominant negative, or potentially hypermorphic variants 
that affect MYRF homotrimerization, autoproteolysis, or 
transcriptional activity.
Conspicuous exceptions to this include recently 
described variants in nanophthalmos [16], such as two inde-
pendent frameshift variants affecting codon 264 (c.789delC, 
c.789dupC). One of these variants (NM_001127392.3, 
c.789dupC, p.(S264Qfs*74)) was also reported in a syndromic 
case of extreme axial hyperopia with mitral valve prolapse, 
unilateral cryptorchidism, and micropenis [14]. All three 
frameshift variants alter the length of an eight nucleotide 
cytosine mononucleotide repeat, and therefore, are a likely 
consequence of slipped-strand mispairing [30], but highlight 
that even N-terminal MYRF frameshift variants can lead to 
isolated nanophthalmos.
Variation in MYRF represents one of only two known 
genetic causes of autosomal dominant nanophthalmos. 
The second is TMEM98, first reported in a large European 
kindred [8]. MYRF encodes a membrane-bound transcription 
factor, which releases an active transcription factor complex 
after homotrimerization and autoproteolytic cleavage [31-33]. 
One of the transcriptional targets of this complex is TMEM98, 
and the TMEM98 protein itself binds directly to MYRF in 
the ER, where it acts as an inhibitor of MYRF autoproteolysis 
and nuclear translocation [34].
Studies in mice have suggested that variants in TMEM98 
associated with nanophthalmos represent gain-of-function 
alleles [35], which, in turn, would be predicted to increase 
inhibitory activity against MYRF. Although we cannot 
exclude the possibility of hypermorphic effects of certain 
MYRF alleles, reduced MYRF activity would be consistent 
with the predicted dominant-negative or loss-of-function 
effect of MYRF alleles suggested elsewhere [15,16], with 
similar support from the small eye phenotype of myrf knock-
down zebrafish [15]. This intimate connection of two genes 
associated with nanophthalmos and high hyperopia provides 
further support for their roles in ocular development.
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